Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
Retrieved on:
Wednesday, August 9, 2023
BioNTech, CT, Nephrotoxicity, IV, Diabetes, Hospital, Mucor, Conference call, Clinical trial, Women's Hospital International and Fertility Centre, Infection, Brain, LNC, Research, Biomedical Research, European Congress of Ethnic Religions, Messenger, Lung, Acute myeloid leukemia, Development, MRI, Kidney, National Resilience Institute, ECCMID, MD, Patient, Standard of care, Azole, Microsoft Access, RNA interference, Fungal infection, FDA, Nationwide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Conference, NYSE, Food, Female, Pharmaceutical industry, Medical imaging, Antifungal
BEDMINSTER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.
Key Points:
- Matinas’ collaboration with National Resilience continues to focus on in vitro and in vivo delivery of mRNA and expects initial data later in 2023.
- The Company reported no revenue for the second quarter of 2023 compared with $1.1 million of revenue for the second quarter of 2022, which was generated from the Company’s research collaborations with BioNTech SE.
- Total costs and expenses for the second quarter of 2023 were $6.2 million compared with $7.0 million for the second quarter of 2022.
- The net loss for the second quarter of 2023 was $6.1 million, or $0.03 per share, compared with a net loss for the second quarter of 2022 of $5.9 million, or $0.03 per share.